This inventor holds 22 USPTO granted patents, plus 20 CIPO patents and 22 EPO patents, primarily in TNF Modulators. Top assignee: Ucb Biopharma Sprl. Active years: 2016-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2019
Areas of Expertise:
Title: Victoria Elizabeth Jackson: Innovator in TNF Modulation
Introduction: Victoria Elizabeth Jackson, based in Slough, Great Britain, is a distinguished inventor with an impressive portfolio of 22 patents. Her innovative contributions to the field of medicine focus primarily on modulating TNF (Tumor Necrosis Factor) activity, which has significant implications for various human health disorders.
Latest Patents: Among her latest patents are groundbreaking inventions that feature:
1. **Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity** - This patent describes a series of substituted fused tricyclic imidazo pyrazine derivatives, which are potent modulators of human TNFα activity. This innovation is beneficial in treating or preventing a range of conditions including autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders.
2. **Imidazothiazole Derivatives as Modulators of TNF Activity** - Another remarkable patent involves substituted imidazo[2,1-b]thiazole derivatives, which also serve as effective modulators of human TNFα activity. Similar to her previous inventions, these derivatives aim at addressing various maladies spanning from autoimmune and inflammatory disorders to oncological challenges.
Career Highlights: Victoria currently works at UCB Biopharma Sprl, where she continues to develop innovative solutions that impact patient care positively. Her extensive research and development experience are evident in her numerous patents that push the boundaries of medical science.
Collaborations: Victoria has collaborated with esteemed colleagues such as Boris Kroeplien and John Robert Porter. Together, they contribute to a vibrant research environment that prioritizes advancements in medical treatments.
Conclusion: Victoria Elizabeth Jackson stands out as a leading innovator in the pharmaceutical field. Her contributions, particularly in the modulation of TNF activity, underline her commitment to improving healthcare outcomes. With her continually expanding patent portfolio, Jackson remains a key player in medical research and innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile